Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.

Eryılmaz R, Keleş MF, Aslan R, Huyut Z, Demir M, Ertaş K, Sevim M, Taken K

Open source

DOI
10.1016/j.urolonc.2026.08.027
Published
2026 Sep 26
Container
Urologic oncology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.urolonc.2026.08.027,
  title = {Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.},
  author = {Eryılmaz R and Keleş MF and Aslan R and Huyut Z and Demir M and Ertaş K and Sevim M and Taken K},
  year = {2026},
  journal = {Urologic oncology},
  doi = {10.1016/j.urolonc.2026.08.027},
  url = {https://doi.org/10.1016/j.urolonc.2026.08.027}
}

RIS

TY  - JOUR
TI  - Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.
AU  - Eryılmaz R
AU  - Keleş MF
AU  - Aslan R
AU  - Huyut Z
AU  - Demir M
AU  - Ertaş K
AU  - Sevim M
AU  - Taken K
PY  - 2026
JO  - Urologic oncology
DO  - 10.1016/j.urolonc.2026.08.027
UR  - https://doi.org/10.1016/j.urolonc.2026.08.027
ER  - 

APA

R, E., MF, K., R, A., Z, H., M, D., K, E., M, S., & K, T. (2026). Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.. Urologic oncology. https://doi.org/10.1016/j.urolonc.2026.08.027

Source records